[Home ] [Archive]    
:: Main About journal Editorial Board Current Issue Archive Submit an article Site Map Contact ::
:: Volume 11, Issue 1 (3-2022) ::
Int J Med Invest 2022, 11(1): 63-72 Back to browse issues page
Comparison of the Effect of Clemestine and Placebo after Intravenous Corticosteroids in the Treatment of Acute Optic Neuritis
Nastaran Majdinasab, Susan Ghasemi * , Maryam Kouchak
Neurology department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract:   (545 Views)
Introduction: Acute optic neuritis is a demyelinating disease of optic nerve and the most common optic neuropathy that affects young adults. Clemastine is a common antihistamine and it plays a main role in restoring the myelin membrane and increase the differentiation of oligodendrocytes.
Methods: In current clinical trial, 30 patients aged 15-50 years with acute optic neuritis were randomly divided into two groups of case and control. The case group was treated with Clemastine for three months and the control group was given a placebo for three months. Visual acuity, color vision, and p100 latency were examined and compared in both groups before and 3 months after the treatment.
Results: The mean color vision after treatment in the case (19.86 ± 0.51) and placebo (19.46 ±1.12) groups showed no statistically significant differences (p> 0.05). Also, the mean visual acuity in the case (0.98 ± 0.056) and placebo (0.94 ± 0.091) groups after receiving medicine showed no statistically significant differences (p> 0.05). The mean of the p100 latency of evoked potential in the case (115.80 ± 13.25) and placebo groups (124.12 ± 7.88) after receiving treatments showed a meaningful difference statistically (p <0.05).
Conclusion: The use of Clemastine for reduction of the chronic complications of the optic neuritis could be considered in the outline.
Keywords: Acute Optic Neuritis, Clemastine, P100 Latency
Full-Text [PDF 268 kb]   (53 Downloads)    
Type of Study: Research | Subject: General
References
1. 1. Beck, R.W., Cleary, P.A., Anderson, M.M., Keltner, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. New England Journal of Medicine. 1992; 326(9): 581-588. DOI: 10.1056/NEJM199202273260901. 2. Torres, R., Sanchez-Dalmau, B.F. Treatment of acute optic neuritis and vision complaints in Multiple Sclerosis. Current treatment options in neurology. 2015; 17(1): 1-11. DOI: 10.1007/s11940-014-0328z . 3. Wilhelm, H., Schabet, M. The diagnosis and treatment of optic neuritis. . Deutsches Ärzteblatt International. 2015; 112(37): p.616. DOI: 10.3238/arztebl.2015.0616. 4. Monteiro, M.L., Borges, W.I., Ramos, C.D., et al. Bilateral optic neuritis in wegener granulomatosis. Journal of Neuro-ophthalmology.2005; 25(1): 25-28. DOI: 10.1097/00041327-200503000-00007. 5. Steed, D.L., Brown, L.R., inventors; Stemnion, L.L.C., assignee. Methods for preventing or treating optic neuritis. US patent application US 14/183,780. 2014 Aug 28. 6. Wakakura, M., Minei-Higa, R., Oono, S., et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Japanese journal of ophthalmology. 1999; 43(2): 127-32. DOI: 10.1016/s0021-5155(98)00072-0. 7. Lee, S.B., Lee, E.K., Kim, J.Y. Bilateral optic neuritis in leprosy. Canadian Journal of Ophthalmology. 2009; 44(2): 219-220. DOI: 10.3129/i09-013. 8. Hoorbakht, H., Bagherkashi, F. Optic neuritis, its differential diagnosis and management. The open ophthalmology journal. 2012; 6: 65-72. DOI: 10.2174/1874364101206010065. 9. Malik. A., Ahmed. M., Golnik, K. Treatment options for atypical optic neuritis. Indian journal of ophthalmology. 2014; 62(10): 982-984. Doi: 10.4103/0301-4738.145986 10. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Archives of neurology. 2008; 65(6): 727-732. doi: 10.1001/archneur.65.6.727. 11. Sellebjerg, F., Nielsen, H.S., Frederiksen, J., et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999; 52(7): 1479 -1494. DOI: 10.1212/wnl.52.7.1479. 12. Gal, R.L., Vedula, S.S., Beck, R. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews. 2015(8): CD001430. Doi: 10.1002/14651858.CD001430.pub3. 13. Mei, F., Fancy, S.P., Shen, Y.A., et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nature medicine. 2014; 20(8): 954-960. DOI: 10.1038/nm.3618. 14. Liu, J., Dupree, J.L., Gacias, M., et al. Clemastine enhances myelination in the prefrontal cortex and rescues behavioral changes in socially isolated mice. Journal of Neuroscience. 2016; 36(3): 957-962. DOI: 10.1523/JNEUROSCI.3608-15. 15. Green, A.J., Gelfand, J.M., Cree, B.A., et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet, 2017; 390(10111): 2481-2489. DOI: 10.1016/S0140-6736(17)32346-2. 16. Li, Z., Yangtao, H., Shuangyi, F., et al. Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination. Neuroscience bull. 2015; 31(5): 617-625. Doi: 10.1007/s12264-015-1555-3. 17. Woron, J., Porębski, G., Obtułowicz, K., et al. Drug safety in pharmacotherapy of allergic diseases. Alergol. Immunol. 2007; 4 (1-2): 22-24. 18. Minigh, J. Clemastine. xPharm. The Comprehensive Pharmacology Reference, 2008; 1–6. ISBN: 978-0-08-055232-3 19. Han, S., Karlowicz-Bodalska, K., Miœkiewicz, K. Safety of oral clemastine–analysis of data from spontaneous reporting system in poland. Tropical Journal of Pharmaceutical Research. 2014; 13(12); 2115-2118. DOI: 10.4314/tjpr.v13i12.24. 20. Mei, F., Lehmann-Horn, K., Shen, Y.A., et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016; (27)5: e18246. DOI: 10.7554/eLife.18246
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Majdinasab N, Ghasemi S, Kouchak M. Comparison of the Effect of Clemestine and Placebo after Intravenous Corticosteroids in the Treatment of Acute Optic Neuritis. Int J Med Invest. 2022; 11 (1) :63-72
URL: http://intjmi.com/article-1-727-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 1 (3-2022) Back to browse issues page
International Journal of Medical Investigation
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4410